{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:49:31Z","timestamp":1767926971604,"version":"3.49.0"},"reference-count":73,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["CMRPG3J1371"],"award-info":[{"award-number":["CMRPG3J1371"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with substantial risks of adverse cardiovascular events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The relevant outcomes associated with the use of a sodium\u2013glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonists (GLP-1RAs) among patients with type 2 diabetes (T2D) with\/without concomitant AF remain unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this nationwide retrospective cohort study from the Taiwan National Health Insurance Research Database, there were 344 392 and 31 351 patients with T2D without AF, and 11 462 and 816 T2D patients with AF treated with SGLT2is and GLP-1RAs, respectively, from May 1, 2016, to December 31, 2019. Patients were followed from the drug index date until the occurrence of study events, discontinuation of the index drug, or the end of the study period (December 31, 2020), whichever occurred first. We used propensity score\u2013stabilized weight to balance covariates across the 2 medication groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The incidence rate of all study outcomes in patients with concomitant AF was much higher than in those without concomitant AF. For the AF cohort, SGLT2i vs GLP-1RA was associated with a lower risk of hospitalization for heart failure (HF) (2.32 vs 4.74 events per 100 person-years; hazard ratio [HR] 0.48, 95% CI 0.36-0.66), with no benefit seen for the non-AF cohort (P for homogeneity &amp;lt; .01). SGLT2i vs GLP-1RA was associated with a lower risk of composite kidney outcomes both in the AF (0.38 vs 0.79 events per 100 person-years; HR 0.47; 95% CI 0.23-0.96) and the non-AF cohorts (0.09 vs 0.18 events per 100 person-years; HR 0.53; 95% CI 0.43-0.64). There were no significant differences in the risk of major adverse cardiovascular events and all-cause mortality in those who received SGLT2i compared with GLP-1RA for the AF or non-AF cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Considering the high risk of developing HF and\/or high prevalence of concomitant HF in patients with concomitant diabetes and AF, whether SGLT2is should be the preferred treatment to GLP-1RAs for such a high-risk population requires further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae157","type":"journal-article","created":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T15:04:24Z","timestamp":1710083064000},"page":"2617-2629","source":"Crossref","is-referenced-by-count":7,"title":["SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With\/Without Atrial Fibrillation"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1406-8503","authenticated-orcid":false,"given":"Yi-Hsin","family":"Chan","sequence":"first","affiliation":[{"name":"The Cardiovascular Department, Chang Gung Memorial Hospital at Linkou , Taoyuan City 333 , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan City 333 , Taiwan"},{"name":"School of Traditional Chinese Medicine, College of Medicine, Chang-Gung University , Taoyuan City 333 , Taiwan"},{"name":"Microscopy Core Laboratory, Chang Gung Memorial Hospital at Linkou , Taoyuan City 333 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6587-3094","authenticated-orcid":false,"given":"Tze-Fan","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital , Taipei 11217 , Taiwan"},{"name":"Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University , Taipei 112304 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-1295","authenticated-orcid":false,"given":"Shao-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan City 333 , Taiwan"},{"name":"Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center , Taoyuan City 333 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Fu","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan City 333 , Taiwan"},{"name":"Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University , Taoyuan City 333 , Taiwan"},{"name":"Division of Cardiology, Department of Medicine, New Taipei City Municipal Tucheng Hospital (Chang Gung Memorial Hospital, Tucheng Branch, Taiwan) , New Taipei City 236 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Ru","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Medicine, Chang Gung University , Taoyuan City 333 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Hsin","family":"Yeh","sequence":"additional","affiliation":[{"name":"The Cardiovascular Department, Chang Gung Memorial Hospital at Linkou , Taoyuan City 333 , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan City 333 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Tai","family":"Kuo","sequence":"additional","affiliation":[{"name":"The Cardiovascular Department, Chang Gung Memorial Hospital at Linkou , Taoyuan City 333 , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan City 333 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-8969","authenticated-orcid":false,"given":"Lai-Chu","family":"See","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Medicine, Chang Gung University , Taoyuan City 333 , Taiwan"},{"name":"Biostatistics Core Laboratory, Molecular Medicine Research Center, Chang Gung University , Taoyuan City 333 , Taiwan"},{"name":"Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital , Taoyuan City 333 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool L69 3BX , UK"},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg 9000 , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"issue":"38","key":"2024091609265488800_dgae157-B1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"2024091609265488800_dgae157-B2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-022-01473-0","article-title":"Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation","volume":"21","author":"Papazoglou","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2024091609265488800_dgae157-B3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12933-020-01043-2","article-title":"Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants","volume":"19","author":"Chan","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2024091609265488800_dgae157-B4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","article-title":"Atrial fibrillation and diabetes Mellitus","volume":"74","author":"Wang","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2024091609265488800_dgae157-B5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 Focused update consensus guidelines of the Asia pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"issue":"22","key":"2024091609265488800_dgae157-B6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2024091609265488800_dgae157-B7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2024091609265488800_dgae157-B8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"2024091609265488800_dgae157-B9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"2024091609265488800_dgae157-B10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"2024091609265488800_dgae157-B11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"2024091609265488800_dgae157-B12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"10157","key":"2024091609265488800_dgae157-B13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"2024091609265488800_dgae157-B14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jfma.2019.02.016","article-title":"Executive summary of the DAROC clinical practice guidelines for diabetes care-2018","volume":"119","author":"Diabetes Association of the Republic of China Taiwan","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"2024091609265488800_dgae157-B15","doi-asserted-by":"crossref","first-page":"109146","DOI":"10.1016\/j.diabres.2021.109146","article-title":"Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with\/without albuminuria: a systematic review and network meta-analysis","volume":"183","author":"Kawai","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"2024091609265488800_dgae157-B16","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"2024091609265488800_dgae157-B17","author":"National Health Insurance Administration, Ministry of Health and Welfare, Taiwan"},{"key":"2024091609265488800_dgae157-B18","author":"Chan","year":"2024"},{"key":"2024091609265488800_dgae157-B19","author":"Chan","year":"2024"},{"issue":"2","key":"2024091609265488800_dgae157-B20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"issue":"4","key":"2024091609265488800_dgae157-B21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1037\/1082-989X.9.4.403","article-title":"Propensity score estimation with boosted regression for evaluating causal effects in observational studies","volume":"9","author":"McCaffrey","year":"2004","journal-title":"Psychol Methods"},{"issue":"3","key":"2024091609265488800_dgae157-B22","doi-asserted-by":"crossref","first-page":"e18174","DOI":"10.1371\/journal.pone.0018174","article-title":"Weight trimming and propensity score weighting","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"issue":"25","key":"2024091609265488800_dgae157-B23","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2024091609265488800_dgae157-B24","volume-title":"Biostatistical Analysis","author":"Jerrold","year":"1996","edition":"4th ed"},{"key":"2024091609265488800_dgae157-B25","volume-title":"Modern Epidemiology","author":"Rothman","year":"1986"},{"issue":"7","key":"2024091609265488800_dgae157-B26","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"6","key":"2024091609265488800_dgae157-B27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"2024091609265488800_dgae157-B28","author":"Chan","year":"2024"},{"key":"2024091609265488800_dgae157-B29","author":"Chan","year":"2024"},{"key":"2024091609265488800_dgae157-B30","author":"Chan","year":"2024"},{"key":"2024091609265488800_dgae157-B31","author":"Chan","year":"2024"},{"key":"2024091609265488800_dgae157-B32","author":"Chan","year":"2024"},{"issue":"1","key":"2024091609265488800_dgae157-B33","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"key":"2024091609265488800_dgae157-B34","author":"Chan","year":"2024"},{"key":"2024091609265488800_dgae157-B35","author":"Chan","year":"2024"},{"issue":"12","key":"2024091609265488800_dgae157-B36","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"issue":"11","key":"2024091609265488800_dgae157-B37","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"15","key":"2024091609265488800_dgae157-B38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes Mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"2024091609265488800_dgae157-B39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ejhf.1663","article-title":"Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial","volume":"22","author":"Bohm","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2024091609265488800_dgae157-B40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjcard.2022.05.017","article-title":"Effect of sodium-glucose cotransporter inhibitors on major adverse cardiovascular events and hospitalization for heart failure in patients with type 2 diabetes Mellitus and atrial fibrillation","volume":"178","author":"Kwon","year":"2022","journal-title":"Am J Cardiol"},{"issue":"5","key":"2024091609265488800_dgae157-B41","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/cvr\/cvz323","article-title":"Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes","volume":"116","author":"Heuvelman","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2024091609265488800_dgae157-B42","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 receptor expression within the human heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"issue":"2","key":"2024091609265488800_dgae157-B43","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2337\/dc15-1437","article-title":"Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using holter electrocardiography and power spectrum analysis of heart rate variability","volume":"39","author":"Nakatani","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"2024091609265488800_dgae157-B44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.hrthm.2015.08.028","article-title":"Heart rate and adverse outcomes in patients with atrial fibrillation: a combined AFFIRM and AF-CHF substudy","volume":"13","author":"Andrade","year":"2016","journal-title":"Heart Rhythm"},{"issue":"6","key":"2024091609265488800_dgae157-B45","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee","volume":"77","author":"Writing","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2024091609265488800_dgae157-B46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-016-0490-6","article-title":"Differential effects of glucagon-like peptide-1 receptor agonists on heart rate","volume":"16","author":"Lorenz","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"2024091609265488800_dgae157-B47","doi-asserted-by":"crossref","first-page":"e004551","DOI":"10.1161\/CIRCHEARTFAILURE.117.004551","article-title":"Is the way to someone\u2019s heart through their stomach? The cardiorenal paradox of incretin-based hypoglycemic drugs in heart failure","volume":"10","author":"Packer","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"12","key":"2024091609265488800_dgae157-B48","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"issue":"21","key":"2024091609265488800_dgae157-B49","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2024091609265488800_dgae157-B50","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"2024091609265488800_dgae157-B51","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"2024091609265488800_dgae157-B52","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2024091609265488800_dgae157-B53","doi-asserted-by":"crossref","first-page":"101390","DOI":"10.1016\/j.diabet.2022.101390","article-title":"Antidiabetic agents and risk of atrial fibrillation\/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab"},{"issue":"1","key":"2024091609265488800_dgae157-B54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-022-01549-x","article-title":"The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","volume":"21","author":"Chan","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2024091609265488800_dgae157-B55","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-022-01572-y","article-title":"Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study","volume":"21","author":"Baviera","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2024091609265488800_dgae157-B56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ehjcvp\/pvab053","article-title":"Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes","volume":"8","author":"Norgaard","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"2024091609265488800_dgae157-B57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-021-01258-x","article-title":"Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","volume":"20","author":"Lugner","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2024091609265488800_dgae157-B58","doi-asserted-by":"crossref","first-page":"e019356","DOI":"10.1161\/JAHA.120.019356","article-title":"Cardiovascular events, acute hospitalizations, and mortality in patients with type 2 diabetes Mellitus who initiate empagliflozin versus liraglutide: a comparative effectiveness study","volume":"10","author":"Thomsen","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2024091609265488800_dgae157-B59","doi-asserted-by":"crossref","first-page":"e022376","DOI":"10.1161\/JAHA.121.022376","article-title":"Cardiovascular effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in older patients in routine clinical care with or without history of atherosclerotic cardiovascular diseases or heart failure","volume":"11","author":"Htoo","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"2024091609265488800_dgae157-B60","doi-asserted-by":"crossref","first-page":"e2237606","DOI":"10.1001\/jamanetworkopen.2022.37606","article-title":"Comparative effectiveness of empagliflozin vs liraglutide or sitagliptin in older adults with diverse patient characteristics","volume":"5","author":"Htoo","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2024091609265488800_dgae157-B61","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.7326\/M21-0893","article-title":"Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease","volume":"174","author":"Patorno","year":"2021","journal-title":"Ann Intern Med"},{"issue":"1","key":"2024091609265488800_dgae157-B62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12933-023-01784-w","article-title":"Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction","volume":"22","author":"Gonzalez","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2024091609265488800_dgae157-B63","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"key":"2024091609265488800_dgae157-B64","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2022.01.042","article-title":"Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice","volume":"352","author":"Fu","year":"2022","journal-title":"Int J Cardiol"},{"issue":"3","key":"2024091609265488800_dgae157-B65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.14598","article-title":"The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a Scandinavian cohort study","volume":"24","author":"Ueda","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2024091609265488800_dgae157-B66","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/dom.14741","article-title":"Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"24","author":"Dong","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2024091609265488800_dgae157-B67","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan\u2019s national health insurance research database: past and future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2024091609265488800_dgae157-B68","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2147\/CLEP.S273853","article-title":"Performance of ICD-10-CM diagnosis codes for identifying acute ischemic stroke in a national health insurance claims database","volume":"12","author":"Hsieh","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"7","key":"2024091609265488800_dgae157-B69","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/pds.5608","article-title":"Validation of diagnosis codes in healthcare databases in Taiwan, a literature review","volume":"32","author":"Huang","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024091609265488800_dgae157-B70","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/CLEP.S353435","article-title":"Validation of stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage on Taiwan\u2019s national health insurance claims data","volume":"14","author":"Hsieh","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"1","key":"2024091609265488800_dgae157-B71","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.ajkd.2010.05.013","article-title":"Validation of CKD and related conditions in existing data sets: a systematic review","volume":"57","author":"Grams","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2024091609265488800_dgae157-B72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4070\/kcj.2012.42.1.10","article-title":"Validity of the diagnosis of acute myocardial infarction in Korean national medical health insurance claims data: the Korean heart study (1)","volume":"42","author":"Kimm","year":"2012","journal-title":"Korean Circ J"},{"issue":"4","key":"2024091609265488800_dgae157-B73","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1253\/circj.CJ-22-0566","article-title":"Validity of diagnostic algorithms for cardiovascular diseases in Japanese health insurance claims","volume":"87","author":"Kanaoka","year":"2023","journal-title":"Circ J"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae157\/57208409\/dgae157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/2617\/59135762\/dgae157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/2617\/59135762\/dgae157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T09:29:30Z","timestamp":1726478970000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/10\/2617\/7625549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":73,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,3,11]]},"published-print":{"date-parts":[[2024,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae157","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,3,11]]}}}